Chris Chen, chief executive of China’s WuXi Biologics, expects approval for a coronavirus antibody treatment either “late this year or early next year, ” he told CNBC. WuXi Biologics, which sells outsourced laboratory and manufacturing services to biotech companies, has signed several deals with clients to research antibodies for delivering coronavirus treatments. Some major progress is going on with these treatments,” he told Emily Tan, speaking to CNBC as part of the annual East Tech West conference. WuXi Biologics, which has operations in the United States, Europe and Singapore in addition to China, will continue to invest in global biotech companies, he said. China has made huge strides in the health care sector, but there is “still a lot of catch-up work to be done,” Chen said.

Source: The Standard November 19, 2020 03:45 UTC